Stryckmans P, De Witte T, Bitar N, Marie J P, Suciu S, Solbu G, Debusscher L, Bury J, Peetermans M, Andrien J M
Semin Oncol. 1987 Jun;14(2 Suppl 1):67-72.
During A-ALL induction treatment, HD-ara-C (2.5 g/m2 IV, day 1), does not produce any beneficial effect, whereas the hematologic toxicity is increased. A 3-month consolidation phase comprising intermittent MTX, ara-C and 6-TG is not significantly affecting either DFI or survival in A-ALL. The association of HD-ara-C and m-AMSA appears to be a promising salvage therapy for the 20% A-ALL refractory to first induction therapy. The quality of autologous bone marrow graft, harvested after HD-ara-C, seems to be impaired as suggested by a delayed recovery of PMN and platelets. HD-ara-C (3 g/m2 X N) given the days before cyclophosphamide and TBI as conditioning treatment for BMT does not seem to induce prohibitory additional toxicity. Whether HD-ara-C was given four to six times or eight to 12 times gave no significant difference in early toxicity.
在急性淋巴细胞白血病（A-ALL）诱导治疗期间，大剂量阿糖胞苷（HD-ara-C，2.5 g/m²静脉注射，第1天）未产生任何有益效果，反而血液学毒性增加。为期3个月的巩固期，包括间歇性甲氨蝶呤（MTX）、阿糖胞苷和6-硫鸟嘌呤（6-TG），对A-ALL的无病生存期（DFI）或生存率均无显著影响。大剂量阿糖胞苷与米托蒽醌联合使用，对于20%对首次诱导治疗无效的A-ALL患者而言，似乎是一种有前景的挽救疗法。如中性粒细胞（PMN）和血小板恢复延迟所示，在大剂量阿糖胞苷治疗后采集的自体骨髓移植质量似乎受损。在环磷酰胺和全身照射（TBI）前几天给予大剂量阿糖胞苷（3 g/m²×N）作为骨髓移植（BMT）的预处理，似乎不会引发额外的严重毒性。大剂量阿糖胞苷给药4至6次或8至12次，早期毒性无显著差异。
